Ianalumab+standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment ...
Dec 9, 2025
0
9









